Ernexa Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Ernexa Therapeutics Inc. (formerly Eterna Therapeutics Inc., rebranded in March 2025) is a preclinical-stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing innovative, off-the-shelf, allogeneic cell therapies for advanced solid tumors and autoimmune diseases. Its core technology platform utilizes engineered induced pluripotent stem cells (iPSCs) differentiated into induced mesenchymal stem cells (iMSCs). This approach leverages the natural tumor-homing and inflammation-homing capabilities of MSCs to deliver potent therapeutic payloads, such as pro-inflammatory or anti-inflammatory cytokines, directly to the target microenvironment without requiring patient-specific cell harvesting.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing lead candidate ERNA-101 from preclinical validation to active clinical trials, supported by completed manufacturing process development and ongoing GMP production.
Expected impact: Establishes clinical proof-of-concept for the engineered iMSC platform and drives long-term shareholder value.
Rebranding the company from Eterna Therapeutics Inc. to Ernexa Therapeutics Inc. to better align corporate identity with its advanced engineered iMSC cell therapy platform.
Expected impact: Clarifies market positioning and focuses investor attention on the off-the-shelf cell therapy pipeline.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Focuses on Engineering, Differentiation, and Production (EDP) activities to support current Good Manufacturing Practice (cGMP) development and scale-up of ERNA-101 in preparation for clinical trials.
Terms: Terms not publicly disclosed.
Collaborating with leading oncologist Dr. Michael Andreeff to pioneer and validate the preclinical efficacy of ERNA-101, demonstrating complete tumor clearance in syngeneic ovarian cancer models.
Terms: Supported by the launch of a Texas-based subsidiary to facilitate ongoing research and clinical development.
Provides Ernexa with a license to utilize cutting-edge gene-editing and cell therapy technologies to engineer its induced pluripotent stem cells (iPSCs).
Terms: Terms not publicly disclosed.